We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.57 | -1.14% | 49.46 | 48.68 | 49.90 | 49.47 | 48.27 | 49.04 | 4,596,609 | 23:02:26 |
From May 2019 to May 2024
By Stephen Nakrosis
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Monday announced the U.S. Food and Drug Administration gave its approval for Dupixent as a treatment for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis.
Atopic dermatitis causes skin to become red, itchy and scaly.
A Phase 3 trial evaluating Dupixent monotherapy in adolescent patients with uncontrolled moderate-to-severe atopic dermatitis demonstrated the safety and efficacy generally were consistent with that previously seen in adult studies, the companies said.
Dupixent also is approved in the U.S. for the treatment of some adult patients with eczema and for use with other asthma medicines for maintenance treatment of moderate-to-severe asthma in some patients people aged 12 years and older.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 11, 2019 16:18 ET (20:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
